Kornimate/medical-research-clean huggingface dataset:
evaluation of the serum markers sflt1 and plgf for the prediction of the complications of the placental vascular pathologies in the 3rd quarter of the pregnancy.

Conditions: Pre-Eclampsia; HELLP Syndrome; Fetal Death; Eclampsia; Placental Abruption; Fetal Growth Retardation, Antenatal

Summary: the pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies.the pre-eclampsia can evolve into severe maternal and\\or foetal complications and is a major cause of mortality. the purpose of the study will to estimate the relevance of the serum markers sflt1 and plgf to predict the arisen of severe complications at these patients, what would allow to decrease the materno-fœtale morbi-mortality due to the pathology.

the pre-eclampsia is a frequent pathology, concerning approximately 5 % of the pregnancies. it is a major cause of mortality, mainly in the developing country. his incidence tends to increase in the developed countries. in the absence of adapted coverage, the pre-eclampsia can evolve into severe maternal and\\or foetal complications (eclampsia, foetal intra-uterine, dead hellp syndrome, lung acute oedema, stunting in utero). the pre-eclampsia is a part of placental vascular pathologies. several studies showed that these pathologies are due to a defect of trophoblastic invasion, secondary in an imbalance in the balance of factors pro and antiangiogéniques (plgf, sflt1). studies also demonstrated that, for a patient presenting a placental vascular pathology, the rate of plgf is decreased and conversely for the rate of sflt1. studies show that the duration of the pregnancy, of a patient presenting a placentary vascular pathology, is correlated at the rate of these markers. there is at present no reliable predictive examination to estimate the arisen of severe complications for a patient presenting a placental vascular pathology. the purpose of the study will to estimate the relevance of the serum markers sflt1 and plgf to predict the arisen of severe complications for these patients.

Eligibility criteria:
inclusion criteria: * pregnant woman with a diagnosis of placental vascular disease (gestational hypertension, preeclampsia, iugr) exclusion criteria: * patient who refuses the obstetric follow-up

Keywords: sflt1 plgf
risk factors of venous thromboembolism after incisional ventral hernia repair.

Conditions: Incisional Hernia; Venous Thromboembolism

Summary: aim of our study is to find frequency and risk factors for venous thromboembolism development in patients who underwent surgery for incisional ventral hernia. there were 240 patients enrolled in our retrospective observational cohort study. included patients were operated for incisional hernia in saveljev university surgery clinic from january 2018 to december 2019. compression duplex ultrasound of lower legs veins was performed in 2-4 days after surgery for all participants. the primary endpoint was the occurrence of the venous thromboembolism event, including pulmonary embolism.


Eligibility criteria:
inclusion criteria: * operated for incisional hernia in saveljev university surgery clinic no exclusion criteria.

Keywords: hernia repair thromboprophylaxis
alpha-1-antitrypsin (aat) to treat emphysema in aat-deficient patients (exactle)

Conditions: Alpha 1-Antitrypsin Deficiency

Summary: the goal of this trial was to explore the utility of evaluating emphysema progression through ct scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (aat; prolastin®). exacerbation data recorded in patient diaries were also collected. all efficacy data were analyzed for potential use in evaluating prolastin efficacy in this and other clinical trials.

this is a one to one randomized, placebo-controlled, clinical, exploratory study with the aim of collecting information on possible clinical endpoints i.e., the progression of emphysema by lung density measurements with ct scan and frequency of exacerbations that could be used for a subsequent placebo controlled clinical trial. progression of disease will be investigated in 80 patients with alpha-1-antitrypsin deficiency, who will be treated with human alpha-1-antitrypsin (aat; prolastin®) or placebo weekly for two years to analyze the effect of treatment on lung density and exacerbations. targeted augmentation therapy with weekly infusions of prolastin® will be a dose of 60 mg/kg body weight (range of 51.72 to 71.43 mg per kg body weight). therefore, this study focuses on several questions: * is the 15th percentile point calculated by analysis of ct lung histograms a useful endpoint for clinical trials in aat deficiency? * is quantitation of exacerbations in aat-deficient patients a useful endpoint for clinical trials in aat deficiency? * are there significant differences between the treatments in favor of prolastin®?

Eligibility criteria:
inclusion criteria: * patient with pulmonary emphysema due to severe congenital aat deficiency of phenotype protease inhibitor z (piz) or other rare genotypes (not ms, mz or sz) and aat serum level \< 11 microns (µm) or \< 80 mg/dl (status to be confirmed by phenotyping and genotyping) * inspiratory capacity (vc - erv) \> 1.2 l and forced expiratory volume at one second (fev1) \< 80% of predicted value post bronchodilator * fev1/vc \< 70% of predicted value post-bronchodilator or transfer factor of carbon monoxide (kco) \< 80% of predicted value post-bronchodilator * history of at least one exacerbation in the past 2 years * written informed consent exclusion criteria: * fev1 \< 25% of predicted value post-bronchodilator * augmentation therapy for more than one month with plasma-derived human alpha 1-antitrypsin (aat) within the last 2 years * history of lung transplant * any lung surgery within the past 2 years * on any thoracic surgery waiting list * diagnosis of liver cirrhosis * severe concomitant disease * active pulmonary infection/exacerbations within the last month * active smoking during the last 6 months or plasma positive for cotinine * body weight \ 92 kg * pregnancy or lactation * women of child-bearing potential without adequate contraception

Keywords: alpha 1 proteinase inhibitor alpha1 proteinase inhibitor congenital emphysema replacement therapy
e-nose: diagnostic tool for pleural tb

Conditions: Tuberculosis, Pleural

Summary: the purpose of this study is to determine the diagnostic utility of the device 'electronic nose' for pleural tb, which is a extra pulmonary tb form, compared with pleural biopsy, the current gold standard.

the aim of the study is to determine the diagnostic utility of the device 'electronic nose' for pleural tb, which is a extra pulmonary tb form. the patient who qualified for the study, according to the inclusion criteria, after consenting, will be guided through and oriented survey for risk factors, then a complete physical exam, and after that, the patient will breathe for 5 minutes trough the device, which stores the patient information, that later will be download to a computer and will be send to the server's manufacturer company, in netherlands. during and after the use of the device, investigators determine the adverse effects of the intervention, according to the ctcea. investigators use the pleural biopsy, which is the gold standard, to determine the diagnostic utility of the test. and, will compare the results with other tests currently perform as the regular diagnostic routine, such as chest ct, adenosine deaminase value of pleural fluid and cytomorphologic \& cytochemistry of the pleural fluid. patient registries will be keep in an electronic database, as well as handwriting history, with the backup copy in the records of the hospital in which the patient was admitted. auditories will be realised by the ethics committee in different time frames.

Eligibility criteria:
inclusion criteria 1. accept to participate in the study through a signed informed consent approved by the ethical committee of our institution. 2. more than 15 years old. 3. pleural effusion of any etiology exclusion criteria: 1. severe compromise of the general condition 2. not capable to exhaled through the e-nose. 3. no possibility to follow-up. 4. by discretion of the research team.
a study of pf-03882845 absorption in healthy volunteers given orally as tablet versus suspension formulations and effect of food on its absorption

Conditions: Diabetes Mellitus, Type 2

Summary: the primary purpose of this study is to estimate the relative bioavailability and food effect of a pf-03882845 tablet as compared to a suspension formulation used in previous clinical studies.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years,females must be of non-childbearing potential. body mass index of 17.5 to 30.5 kg/m2. * subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. exclusion criteria: * serum potassium \>5 meq/l at screening. * impaired kidney function (estimated gfr \<60 ml/min/1.73 m2). history of sensitivity to eplerenone, spironolactone, or related compounds.

Keywords: relative bioavailability food effect tablet suspension single dose crossover healthy subjects
a comprehensive assessment of anterior corneal power by different devices

Conditions: Myopia

Summary: to comprehensively assess the precision and agreement of anterior corneal power measurements using 8 different devices.

volunteers with healthy corneas will be measured by different instruments to detect their anterior corneal power. only the right eye of each subject was selected. measurements were repeated in the second session scheduled 1 to 2 weeks later.

Eligibility criteria:
inclusion criteria: * healthy cornea, * best corrected distance visual acuity (bcva) equal to or better than 20/25, * willing and able to comply with scheduled visits and other study procedures. exclusion criteria: * history of refractive surgery or any keratoplasty procedure, * use of contact lenses, * history of corneal dystrophies or degenerative diseases, * history of glaucoma or ocular hypertension, * significant subjective dry eye symptoms, schirmer i test results of less than 5.0 mm, tear film break-up time shorter than 5 seconds and corneal fluorescein staining positive.

Keywords: anterior corneal power placido topographer scheimpﬂug precision agreement
skin diseases and pregnancy: which heathcare professionals ?

Conditions: Skin Abnormalities; Pregnancy

Summary: pregnancy-induced physiological dermatological changes are common. in 2016, they represented between 23% (acne) and 75% (pigmentary changes) of pregnancies in france. some dermatological changes require medical advice to identify a possible pathological rash. these pathological rashes can be dangerous for the mother or the fetus. the aim of this study is to assess the prevalence of skin diseases during pregnancy and to evaluate the care pathway in a healthcare sector (vendee) for these pregnant women?

pregnancy-induced physiological dermatological changes are common. in 2016, they represented between 23% (acne) and 75% (pigmentary changes) of pregnancies in france. some dermatological changes require medical advice to identify a possible pathological rash. these pathological rashes can be dangerous for the mother or the fetus. it is therefore essential to recognize them for a quick specialized treatment. they include: intrahepatic cholestasis of pregnancy, pemphigoid gestationis, polymorphic eruption during pregnancy, atopic eczema, generalized pustular psoriasis in pregnancy. in view of the demography of dermatologists in the vendee, 18 dermatologists in 2020 in all establishments (hospitals, clinics, practices), the general practitioner is at the center of these considerations. the aim of this study is to assess the situation of skin disease during pregnancy and to evaluate the care pathway in a healthcare sector (vendee) for these pregnant women?

Eligibility criteria:
inclusion criteria: * any woman who gives birth at departmental hospital center of vendee exclusion criteria: * patient's refusal to participate in the study
effects of a multidimensional exercise program on cardiac surgery patients

Conditions: Cardiac Surgery; Frailty

Summary: this randomized controlled trial study aims to examine the effects of a multidimensional exercise program in cardiac surgery patients. the following hypotheses were tested: patients who received the exercise program will report significant improvement in frailty after the 12-week multidimensional exercise program. subjects are randomly assigned to the intervention or control group. patients in the intervention group will receive a 12-week multidimensional exercise program. data are collected by using medical records and structural questionnaires, measuring handgrip strength, and a four-meter walk test at baseline, 6 weeks, and 12 weeks.

this study aims to develop a multidimensional exercise program and examine the effects of an exercise program on cardiac surgery patients. an experimental design is used. subjects are recruited using convenience sampling and randomly assigned to the intervention or control group using the block randomization method. patients in the intervention group will receive a 12-week multidimensional exercise program, including individual nursing consultation, an exercise program that includes moderate intensity walking for 30-45 minutes per day, three days per week combined resistance exercise, nutrition assessment, and instructions, and support. data are collected by using medical records and structural questionnaires, measuring handgrip strength, and a four-meter walk test at baseline, 6 weeks, and 12 weeks. the data were analyzed using spss version 22.0, and data analysis methods include descriptive statistics, independent t-test, chi-square, and generalized estimating equation.

Eligibility criteria:
inclusion criteria: 1. aged above 40 years old and received cardiac surgery via median sternotomy with a stable physical condition; 2. at least met one of the frailty phenotypes, including unintentional weight loss, exhaustion, weakness, slow walking speed, and low physical activity proposed by fried et al. (2001); 3. had clear consciousness (mini-mental state examination score\>24) and can communicate with mandarin or taiwanese; 4. consent to participate in this study. exclusion criteria: 1. bed-ridden, cannot stand or depends on others to complete all activities of daily living; 2. received emergency cardiac surgery; 3. with a mental illness history; 4. had exercise contraindications including: in infectious or acute phases, uncontrolled hypertension, arrhythmia, or diabetes mellitus; 5. had a musculoskeletal disease, which might be aggravated by exercise; 6. participate in phase two of cardiac rehabilitation.

Keywords: cardiac surgery frailty exercise program randomized controlled trial
judging the efficacy of secukinumab in patients with psoriasis using autoinjector: a clinical trial evaluating treatment results (juncture)

Conditions: Plaque-type Psoriasis

Summary: the purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at week 12 based on pasi and iga response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.


Eligibility criteria:
inclusion criteria: * moderate and severe plaque-type psoriasis diagnosed for at least 6 months. * severity of psoriasis disease meeting all of the following three criteria: * psoriasis area and severity index (pasi) score of 12 or greater * investigator's global assessment (iga) score of 3 or greater * total body surface area (bsa) affected of 10% or greater * inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy. exclusion criteria: * current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). * current drug-induced psoriasis. * previous use of secukinumab or any drug that targets il-17 or il-17 receptor. * significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject. * hematological abnormalities. * history of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis. * history of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years. * pregnant or nursing (lactating) women.

Keywords: psoriasis moderate to severe plaque-type psoriasis skin condition skin disease itching condition psoriasis vulgaris relapsing/remitting psoriasis immune-mediated systemic disease skin lesions red skin lesions scaly patches papules plaques itching
a clinical study of kdt-3594 in patients with early parkinson's disease.

Conditions: Parkinson Disease

Summary: objective of this study is to investigate the efficacy, safety and pharmacokinetics of kdt-3594 in patients with early parkinson's disease without a concomitant medication of l-dopa.


Eligibility criteria:
inclusion criteria: * japanese patients * patients who are diagnosed with parkinson's disease according to uk parkinson's disease society brain bank clinical diagnostic criteria * patients with parkinson's disease in stages 1 to 3 on the modified hoehn and yahr scale exclusion criteria: * patients who are suspected any parkinsonism except for idiopathic parkinson's disease * patients who underwent neurosurgical treatment (stereotaxic destruction, deep brain stimulation etc.) for pd, or patients for whom surgical treatment is scheduled during the study * patients with a complication of obvious dementia, or patients with mini-mental state examination (mmse) score \< 24 points
comparative study of polymetric clips (hem-o-lok) versus historical endoscopic staplers for laparoscopic appendectomy

Conditions: Appendicitis

Summary: the purpose of this study is to compare the clinical outcomes and the operative costs of appendectomy performed with the hem-o-lok polymetric clips compared to endoscopic staplers. prospective data will be collected before, during, and after surgery on patients undergoing a laparoscopic appendectomy that have the hem-o-lok ® stapler used to close the stump after the appendix is removed. use of the hem-o-lok ® stapler is standard for appendectomy patients at duke regional hospital. retrospective data will be collected from patients who had an appendectomy prior to 1/2012 using a different clip as part of their surgery, or an open appendectomy to compare outcomes.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. scheduled to undergo a laparoscopic appendectomy because of a diagnosis of appendicitis based on clinical history or radiographic imaging. exclusion criteria: 1. less than 18 years of age 2. signs of appendiceal rupture or abcess on preoperative imaging studies (ct or ultrasound) 3. inability to provide informed consent

Keywords: polymetric clips (hem-o-lok) laparoscopic appendectomy endoscopic staplers
misoprostol in the prevention of postpartum haemorrhage

Conditions: Postpartum Hemorrhage

Summary: postpartum haemorrhage is a major contributor to maternal mortality in the developing world. the incidence is between 5 and 12% in jamaica and varies depending on the route of delivery. misoprostol is a uterotonic agent which has the potential to augment the effects of the standard parenteral oxytocic agents used as best practice in the active management of the third stage of labour, thereby reducing the risk of postpartum haemorrhage and its attendant complications. the aim of the study is twofold: to show that this additive effect translates to a reduced postpartum haemorrhage rate and secondly to demonstrate reduced side effects of misoprostol resulting from the lower dose and the powdered sublingual administration.


Eligibility criteria:
inclusion criteria: * pregnant women admitted to the labour wards at university hospital of the west indies (uhwi) and victoria jubilee hospital (vjh) undergoing a vaginal delivery * consent given to participate in the study exclusion criteria: * women undergoing caesarean section * gestational age less than 28 weeks * any severe allergic conditions * severe asthmatics * age \<16 years * temperature \>38 degrees celsius * women not wishing to consent to join the study
multiple escalating oral doses study of pf-07081532 in adult participants with type 2 diabetes mellitus

Conditions: Diabetes Mellitus Type 2

Summary: this is a randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open, dose-escalating study of pf-07081532 in patients with type 2 diabetes on metformin (parts a and c). the study may also enroll non-diabetic participants with obesity (part b). study participants will receive an investigational product or placebo every day for up to 28 days (part a) or up to 42 days (part b, optional; part c, optional). the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) of multiple oral doses of pf-07081532 in participants with inadequately controlled t2dm on metformin and optionally in non-diabetic obese participants.


Eligibility criteria:
key inclusion criteria for participants enrolling with t2dm: * type 2 diabetes treated with a stable dose of metformin at least 500 mg per day for at least 2 months prior to screening visit and use of no other medications for glycemic control. * hba1c value between 7.0% and 10.5%, inclusive. key exclusion criterion for participants enrolling with t2dm: -type 1 diabetes or secondary forms of diabetes. key inclusion criterion for participants enrolling with obesity: -obese (as indicated by screening bmi) non-diabetic adults. key exclusion criterion for participants enrolling with obesity: --type 1 or type 2 diabetes or secondary forms of diabetes.